Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 1996

View Archived Issues

L-742694: Morpholine-based NK1 antagonist

CP-122721 shows potent affinity for NK1 receptors after oral dosing

Rizatriptan NDA filing expected in mid-1997

Ultiva okayed for marketing in Germany; U.S. approval recommended by committee

Wound-healing peptides claimed by Morinaga Milk

Propecia NDA filing slated for late 1996

Amlexanox approvable in U.S.

L-749345 in clinical trials at Merck & Co.

Antifungal antibiotic YM-47522 isolated by Yamanouchi

Antifungal activity and good tolerability in phase I trial of L-743872

Abelcet approved for marketing in Portugal

Schering-Plough claims antiherpesvirus agents

Japanese researchers present anti-RSV agent at congress

NF-1062 evaluated for activity against rotavirus

NF-1153 demonstrates potent activity against influenza virus

Antiinfluenza activity of LY-180299 described at congress

BW-1263W94 selected for clinical testing in CMV infection

RSV inhibitors presented by Wyeth-Ayerst

Clinical data from Lidakol phase III studies

Preliminary phase II results for HNK20

New allophenylnorstatine protease inhibitors from Japan Energy

So324: Stavudine prodrug with potent anti-HIV activity

AE6C: AZT prodrug with improved toxicity profile

Oral anti-HIV oligosaccharide sulfate derivative presented at antiviral congress

Anti-HIV-1 activity demonstrated in mice by RKS-1443

Excellent anti-HIV exhibited by RD4-2217

Anti-HIV compounds isolated from marine organism

Agouron presents Viracept trial results

PMPA: Candidate for clinical study in AIDS

PRO-2000 begins phase I/II in Europe

Adefovir dipivoxil to enter phase II/III in mid-1996

Crixivan pediatric formulation in development

Ciba-Geigy claims matrix metalloproteinase inhibitors

COX-2 inhibitor selected for further study at Searle

COX-2 inhibitors in clinical trials at Merck & Co.

Update on ConXn clinical progress

HPV vaccine in phase I at Merck & Co.

Merck's pediatric pneumococcal conjugate vaccine in advanced trials

MGI-114 receives patent protection in U.S.

Glaxo Wellcome's new dihydrofolate reductase inhibitor 195U89

Gemzar approved in U.S.

FDA gives go-ahead for 5-FP clinical trials

Ajinomoto reports antitumor antibiotic

Taxotere approved for marketing in U.S.

Paclitaxel-platinum complex combination effective in clinical trials

Patent protection obtained for IDEC-C2B8

Vical, Corixa to collaborate on immunotherapeutic drugs for cancer

Genzyme Transgenics, NCI to collaborate on idiotypic cancer vaccines

ImClone, E. Merck continue cancer vaccine collaboration

Medarex presents MDX-210 phase I/II interim results

Role of DF3 in human carcinoma and potential therapeutics

SU-101 interim results announced at ASCO

Marimastat continues to show clinical efficacy

Ortho claims agents for osteoporosis

Ibandronate demonstrates bone-preserving effects in phase II

Zoledronate effective in Paget's disease patients

Orphan Medical discontinues glucaric acid development

Intrachol receives U.S. patent protection

Amgen begins clinical testing of leptin

RF-1051 receives orphan drug status in PWS

PolyHeme phase II results in trauma patients announced

Atrix completes phase III studies of Atridox

Isis claims oligonucleotides for diagnostic use

Peptide Therapeutics, Dr. Fooke to research arthritis diagnostics

Orphan drug status for CEA-Scan

Eagle Research to license Oral-Assist products

ADIR claims melatonin receptor ligands for CNS disorders

Fujisawa, Nihon Shokubai claim CCK-B antagonists

ICN will market fluoxetine in Russia, ex-Yugoslavia

Bayer, CV Therapeutics collaborate on antiinflammatory drugs

Synthelabo and Genset collaborate on drugs for prostate disorders

Anticancer drug collaboration established by Abbott, University of Pittsburgh

Theracell's Sertoli cell technology for CNS disorders

Baxter will develop graft system developed by Australian investigators

Biogen introduces Avonex in first market

Lilly's new series of muscarinic cholinergic receptor agonists

E. Merck describes NMDA ligands for neurodegeneration

Sankyo's calpain inhibitor for neurological disorders, restenosis

PLA2 inhibitors claimed by AHP for asthma, inflammatory conditions

Zeneca reports antiasthmatic NK1/NK2 antagonists

alpha v/beta 6 gene may be implicated in asthma

NFAT1 protein may be implicated in asthma

Montelukast NDA filing in sight

Pirfenidone clinical trials in pulmonary fibrosis

ADIR claims imidazoline I1 receptor ligands for hypertension

ADIR claims compounds for venous insufficiency

More angiotensin II antagonists from Japanese companies

Progress on endothelin antagonists at Texas Biotechnology

Update on fenoldopam regulatory submission

Transdermal scopolamine studied in hypertensive patients

Medco, Fujisawa to codevelop and comarket adenosine for CABG and AMI

Na+/K+-ATPase inhibitors disclosed by Sigma-Tau

FDA to discuss ProAmatine application

E. Merck claims oxazolidinone adhesion receptor antagonists

Mitsui Toatsu reports bicyclic fibrinogen antagonists

Fibrinogen antagonists claimed by Taisho

VCAM-1/VLA-4 inhibitors in the Texas Biotechnology pipeline

IND filing anticipated for TBC-1269

Tirofiban advances through clinical trials; filing in sight

Sankyo reports 5alpha-reductase inhibitors for BPH

Endothelin antagonists show potential in BPH

Improved tolerance expected with S-doxazosin

Lovastatin potential for use in post-transplant patients

PPS + oxybutinin for interstitial cystitis

L-Arginine shows promise in treatment of interstitial cystitis

5-HT4 antagonist LY-353433: Potential treatment for GI disorders

Orphan Medical obtains European marketing rights for Colomed

TravelGAM clinical results presented at ASM meeting

Tobishi CCK-A antagonists for pancreatitis

Nitto Boseki claims serine protease inhibitors

Role of p140 in diabetes investigated by Ono

Takeda claims antidiabetic and hypolipidemic agents

MacroChem's erectile dysfunction therapy moves to phase I/II in U.S.

Vasomax completes phase II in Germany

Losartan for treatment of erectile dysfunction

Clomipramine for treatment of premature ejaculation

Nitroglycerin gel enhances erectile function in healthy males

Forskolin studied as rescue therapy for impotence

New contraceptives reported by Akzo Nobel

HMR discloses 5-HT reuptake inhibitors

Searle sells shares in Hokuriku

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...